#VisualAbstract Amivantamab-lazertinib is Effective for Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: osimertinib
#VisualAbstract: Amivantamab plus Lazertinib Improves Outcomes in Previously Untreated EGFR-Mutated Advanced NSCLC
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract Osimertinib significantly improved progression-free survival in patients with unresectable stage III non-small cell lung cancer
Click to read the study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
#VisualAbstract: Osimertinib after Chemoradiotherapy Increases Survival in Stage III EGFR-Mutated NSCLC
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Osimertinib significantly improved progression-free survival in patients with unresectable stage III non-small cell lung cancer
1. Treatment with osimertinib significantly improved progression-free survival, compared to placebo, in patients with unresectable stage III EGFR-mutated NSCLC 2. ...
#VisualAbstract: Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Overall Survival Improved with Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC
1. The 5-year overall survival had a hazard ratio of 0.49, and this benefit was generally consistent across subgroups (stage, ...
#VisualAbstract: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in ...
Osimertinib associated with longer overall survival versus comparator EGFR-TKIs
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in ...
Osimertinib improves progression-free survival in EGFR-mutated non-small-cell lung cancer: The FLAURA trial
1. Osimertinib demonstrated a significantly longer duration of progression-free survival compared to standard of care epidermal growth factor receptor (EGFR)-tyrosine ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
